Eli Lilly (LLY)

Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial.

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

A news article implied that the company might have an advantage in the weight loss drug race.

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable strength of its diabetes and obesity care segments. The company's flagship weight-loss drug, Wegovy, and the diabetes treatment Ozempic continued their meteoric

The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.

Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments.

In an otherwise hot stock market, healthcare stocks are underperforming.

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Quality yields above 6% from three very different market sectors.

The weight loss drug market may reach $95 billion within five years.

Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance. However, this impressive growth narrative is punctuated by a revised, lower full-year sales and profit outlook, signaling intensifying competitive pressures

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for 2025, sending ripples through the global anti-obesity drug market. Despite robust initial half-year performance and the surging demand for weight-loss medications, the Danish giant

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor agonists. These revolutionary medications, capable of achieving significant weight loss, are not only transforming the treatment landscape for millions but also igniting a fierce battle among

A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.

They could deliver market-beating returns beyond 2030.

Their prospects look intact despite some recent roadblocks.